A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
The mission of the Motol Teaching Hospital is to treat patients on the basis of current medical science knowledge and to provide their clients with comprehensive and high-quality highly specialized care for all phases of human life. The mission summarizes the motto: fnmotol.cz: we serve generations.
Praha, Czechia Clinical Trial Location
Fackultni Nemocnice v Motole
V Úvalu 84,
150 06 Praha 5, Czechia